SCHEMBL13225552

SCHEMBL13225552

COC(=O)/C=C/c1cnn(-c2ccc(OC)cc2)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
PKM P14618 1/20 0.49
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
KMT2A Q03164 2/20 0.43
S1PR4 O95977 1/20 0.43
ALDH1A1 P00352 1/20 0.43
S1PR1 P21453 1/20 0.43
HTT P42858 1/20 0.43
PAX8 Q06710 1/20 0.43
OXTR P30559 1/20 0.43
MAPK14 Q16539 1/20 0.43
PTGS2 P35354 3/20 0.42
GSK3B P49841 1/20 0.42
MEN1 O00255 1/20 0.42
NPBWR1 P48145 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13225551 0.88 NPC1 (0.53) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL598575 0.80 NPBWR1 (0.55) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL1566835 0.77 NPBWR1 (0.45) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1566833 0.77 NPBWR1 (0.45) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4548376 0.74 PDE4D (0.48) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL2855932 0.73 NPC1 (0.69) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL23400582 0.72 SMN1; SMN2 (0.52) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL12991623 0.72 NPC1 (0.51) NPC1RAB9APKMMAPTSMN1; SMN2
SCHEMBL13933860 0.72 NOTUM (0.42) MAPTSMN1; SMN2NFKB1KMT2AALDH1A1
SCHEMBL13225550 0.71 SMO (0.53) NPC1RAB9APKMMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204278-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204278-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204278-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 NPC1 20/4885RAB9A 2608/4885PKM 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.